Clinical Trial

A Non-interventional Study Investigating Semaglutide in Combination With Lifestyle-based Modifications for the Management of Obesity in Real-World Clinical Practice in Germany (WeGo Real Germany).

Study acronym: WeGoReal
Terminated
View on ClinicalTrials.gov →
Why the trial stopped
The study was cancelled prematurely due to lack of patients.
Summary
Participants will be treated with commercially available semaglutide according to routine clinical practice at the discretion of the treating physician for the management of obesity. The purpose of this study is to collect data on the effect of Semaglutide under everyday conditions in participants. Participants and doctor had already decided that they will get semaglutide prescribed by doctor, independently of patient's participation in this study. The study will last for 12 months.
Protocol Amendment History 4 changes
critical Trial status changed: Enrolling by Invitation → Terminated 2026-04-28
notable Enrollment reduced: 555 -> 100 participants 2026-04-28
notable Primary completion moved earlier: 2027-10-21 -> 2025-12-18 2026-04-28
minor Completion moved earlier: 2027-10-21 -> 2025-12-18 2026-04-28
Trial Details
NCT Number NCT07081178
Lead Sponsor Novo Nordisk A/S
Conditions Obesity
Enrollment 100 participants
Start Date 2025-08-08
Primary Completion 2025-12-18 (estimated)
Study Completion 2025-12-18 (estimated)
Updated on ClinicalTrials.gov 2026-04-27